Infliximab therapy in ulcerative colitis: Initial experience in two referral centers;Tratamiento con infliximab en la colitis ulcerosa: Experiencia inicial en dos centros de referencia

Gastroenterologia y Hepatologia

Volumn 30, Issue 8, 2007, Pages 449-453

  Díez, Marcos ^a   Sánchez, Elena ^b   López, Santiago García ^b   Arroyo, María Teresa ^a   Gomollón, Fernando ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; PREDNISONE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COLON RESECTION; CORTICOSTEROID THERAPY; DESCRIPTIVE RESEARCH; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REMISSION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 36048988081     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13110489     Document Type: Article

References (24)

1. García S, Gomollón F, Gisbert JP. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-14.
2. Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol and Hepatol. 2007;5:103-10.
3. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig Dis Sci. 1996;41:2471-6.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticoesteroid therapy for inflammatory bowel disease. a population-based study. Gastroenterology. 2001;121:255-60.
5. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-9. Gastroenterol Hepatol. 2007;30(8):449-53 453
6. Rutgeerts P, Van Assche G, Vermeire S. Review Article: infliximab therapy for inflammatory bowel disease: seven years on. Aliment Pharmacol Ther. 2006;23:451-63.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
8. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-8.
9. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
10. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-11.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170 Suppl:2-6.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5-36.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955;2:1041-8.
15. Doménech E, Esteve M, Gomollón F, et al. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade) en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2005;28:126-34.
16. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.
17. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-87.
18. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther. 2005;22:907-16.
19. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-5.
20. Arts J, Zeegers M, D'Haens G, et al. Long-term outcome of treatment with cyclosporine IV for patients with intractable ulcerative colitis [abstract]. Gastroenterology. 2001;120 Suppl 1: 624A.
21. López-SanRomán A, Obrador A, Fortín J, Muñoz P, Gassull MA. (GETECCU) Recomendaciones sobre la tuberculosis y el tratamiento de la enfermedad inflamatoria con infliximab. Actualización 2006. Gastroenterol Hepatol. 2006;29:81-4.
22. Gisbert JP, González-Lama Y, Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2006;25:19-37.
23. Bermejo F, López-Sanromán A, Hinojosa J, et al. Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria. Rev Esp Enferm Dig. 2004;96:94-101.
24. Nos Mateu P. Nuevos tratamientos y modalidades diagnósticas en la colitis ulcerosa. Gastroenterol Hepatol. 2006;29 Suppl 3:52-6.